Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) CMO David Shapiro sold 349 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $58.90, for a total transaction of $20,556.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

David Shapiro also recently made the following trade(s):

  • On Friday, September 1st, David Shapiro sold 1,250 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $117.43, for a total transaction of $146,787.50.
  • On Tuesday, August 1st, David Shapiro sold 1,118 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $119.00, for a total transaction of $133,042.00.
  • On Tuesday, July 11th, David Shapiro sold 553 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $124.01, for a total transaction of $68,577.53.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) traded up 4.52% during trading on Wednesday, reaching $68.73. 1,847,081 shares of the company’s stock were exchanged. Intercept Pharmaceuticals, Inc. has a 52 week low of $54.98 and a 52 week high of $156.65. The stock has a 50-day moving average of $94.11 and a 200-day moving average of $111.08. The stock’s market capitalization is $1.73 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.62) by $0.16. The business had revenue of $30.89 million during the quarter, compared to the consensus estimate of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The company’s revenue was up 459.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($3.14) earnings per share. On average, equities research analysts anticipate that Intercept Pharmaceuticals, Inc. will post ($13.99) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Insider Selling: Intercept Pharmaceuticals, Inc. (ICPT) CMO Sells 349 Shares of Stock” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.americanbankingnews.com/2017/10/04/insider-selling-intercept-pharmaceuticals-inc-icpt-cmo-sells-349-shares-of-stock.html.

A number of research firms have recently weighed in on ICPT. JMP Securities cut shares of Intercept Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Wednesday. Royal Bank Of Canada raised their price target on shares of Intercept Pharmaceuticals from $200.00 to $244.00 and gave the company an “outperform” rating in a report on Tuesday, September 26th. Wedbush restated an “outperform” rating and issued a $253.00 price target on shares of Intercept Pharmaceuticals in a report on Friday, August 25th. Needham & Company LLC reaffirmed a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Tuesday, September 26th. Finally, Cantor Fitzgerald reaffirmed an “underweight” rating and issued a $69.00 price objective (up from $60.00) on shares of Intercept Pharmaceuticals in a research report on Monday, July 31st. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Intercept Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $162.88.

Hedge funds have recently bought and sold shares of the company. WFG Advisors LP boosted its holdings in shares of Intercept Pharmaceuticals by 16.4% in the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 125 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock valued at $118,000 after acquiring an additional 132 shares during the period. US Bancorp DE acquired a new stake in shares of Intercept Pharmaceuticals in the first quarter valued at approximately $130,000. IFP Advisors Inc boosted its holdings in shares of Intercept Pharmaceuticals by 128.1% in the second quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock valued at $157,000 after acquiring an additional 730 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in shares of Intercept Pharmaceuticals in the first quarter valued at approximately $170,000. 82.19% of the stock is owned by institutional investors and hedge funds.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.